Received Mar 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y013350 | — |
The HBP stated patient did not experienced any adverse issues or side effects related to the administered VARIVAX dose.; A HBP (responsible for vaccine storage) called to report a TE for VARIVAX that occurred on 02/24/2025 and the vaccine was also inadvertently administered on 02/26/2025.; This spontaneous report was received from an other health professional and refers to a 16-year-old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. It was reported a temperature excursion (TE) for Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) that occurred on 24-Feb-2025. On 26-Feb-2025, the patient was inadvertently received Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), lot #Y013350, expiration date: 02-Aug-2026, 0.5 mL / once as prophylaxis (Product storage error). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT). Operator of device was health professional. It was stated patient did not experienced any adverse issues or side effects related to the administered Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) dose (No adverse event).
Sterile diluent